Handelsavisen
prelaunch
Companies ›Healthcare ›378800.KQ
37
378800.KQ — KOSDAQ Biotechnology & Medical Research

378800.Kq

$1 349,00
Open in Charts → Attach watcher ⌖
— —
KRW
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
62,4B KRW
P/E
—
EV / Rev
—
Div yield
0,00 %
Op margin
-6 852,5 %
ROE
-62,7 %
Net margin
-6 816,3 %
Debt / equity
0,01
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

The company operates in the biotechnology and medical research sector, primarily engaged in pharmaceuticals and medical research activities.

Business. The company operates in the biotechnology and medical research sector, primarily engaged in pharmaceuticals and medical research activities.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
-62,7 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 378800.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 378800.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the biotechnology and medical research sector, primarily engaged in pharmaceuticals and medical research activities.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company maintains a strong liquidity position, as evidenced by a current ratio of 12.53, indicating a significant excess of current assets over current liabilities. The price-to-book ratio of 2.41 suggests that the market values the company at a premium relative to its book value. However, the company's operating cash flow is negative at -14,672,489,470 KRW, and its free cash flow is also negative at -14,762,306,910 KRW, indicating a lack of cash generation from operations.

    Profitability metrics are concerning, with a return on equity of -0.6275 and a return on assets of -0.557, both significantly below the industry norms. The company's operating income is negative at -15,610,411,940 KRW, and its net income is also negative at -15,527,830,200 KRW, reflecting substantial operational losses. The gross profit is negative at -93,270,590 KRW, further underscoring the company's financial challenges.

    The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher risks if the primary market or product line experiences a downturn.

    The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year. Historical revenue data shows a total revenue of 227,804,630 KRW, but the absence of growth metrics makes it difficult to assess future performance. The company's capital expenditure of -404,766,890 KRW indicates a reduction in investment in long-term assets.

    Risk factors include a low liquidity risk and a low dilution risk, as no immediate filing-based liquidity or dilution flags were detected. The debt-to-equity ratio of 0.01 suggests minimal leverage, reducing financial risk. However, the company's negative operating and free cash flows indicate potential liquidity challenges in the future.

    Recent events, as disclosed in the financial statements, include a significant negative operating cash flow and a high market price-to-book ratio. No specific recent filings or transcripts were provided that detail recent strategic or operational developments.

    Key takeaways
    • The company has a strong liquidity position with a current ratio of 12.53.
    • The company is experiencing significant operational losses, with a negative return on equity and return on assets.
    • The company's revenue is concentrated in a single segment, with no geographic diversification disclosed.
    • The company's growth trajectory is uncertain due to the absence of specific growth metrics.
    • The company has a low liquidity and dilution risk, but its negative cash flows may pose future challenges.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $1 349,00
    Market cap
    $59.75B
    Enterprise valueⓘ
    $59.15B
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    2.4x
    P / Tangible bookⓘ
    2.4x
    Tangible book
    $24.74B
    Net cashⓘ
    $594.6M
    Current ratioⓘ
    12.5
    Debt / equityⓘ
    0.0
    ROAⓘ
    -55.7%
    ROEⓘ
    -62.7%
    Cash conversionⓘ
    94.0%
    CapEx / revenueⓘ
    -1.8%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-6 852,5 %Bottom quartile
    Net Margin-6 816,3 %Bottom quartile
    ROE-62,7 %Bottom quartile
    Capex / Rev-177,7 %Bottom quartile
    D/E0,01Above median
    Cash Conv0,94Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • 378800.KQ Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    378800.KQCanonical
    KOSDAQ · KRW

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage